Effect of Secukinumab on Patient‐Reported Outcomes in Patients With Active Ankylosing Spondylitis: A Phase III Randomized Trial (MEASURE 1)

OBJECTIVE: To evaluate the effect of secukinumab (interleukin‐17A inhibitor) on patient‐reported outcomes in patients with active ankylosing spondylitis (AS). METHODS: In this phase III study, 371 patients were randomized (1:1:1) to receive intravenous (IV) secukinumab 10 mg/kg at baseline and weeks...

Descripción completa

Detalles Bibliográficos
Autores principales: Deodhar, Atul A., Dougados, Maxime, Baeten, Dominique L., Cheng‐Chung Wei, James, Geusens, Piet, Readie, Aimee, Richards, Hanno B., Martin, Ruvie, Porter, Brian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2016
Materias:
Spondyloarthritis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5132041/
https://www.ncbi.nlm.nih.gov/pubmed/27390130
http://dx.doi.org/10.1002/art.39805

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5132041/
https://www.ncbi.nlm.nih.gov/pubmed/27390130
http://dx.doi.org/10.1002/art.39805

Ejemplares similares